CHINA GEWANG BIOTECHNOLOGY, INC. - Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Feb. 29, 2016	Feb. 28, 2015
Cash flows from Operating Activities
Net income	$ 350,698	$ 366,966
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	10,108	6,347
Changes in operating assets and liabilities:
(Increase) in accounts receivable	(26,726)	(275,003)
(Increase) in inventory	116,621	(22,412)
(Increase) in prepaid expenses	$ (67,970)	$ (111,690)
(Decrease) in accounts payable
(Decrease) increase in advances from customers		$ (56,930)
Increase in taxes payable	$ 9,448	39,931
Increase (decrease) in accrued liabilities and other payables	(90,631)	23,499
Net cash provided by operating activities	301,548	(29,292)
Cash flows from investing activities:
Purchase of equipment	(78,567)	(732)
Net cash (used in) investing activities	(78,567)	$ (732)
Cash Flows From Financing Activities:
Proceeds from sale of common stock	$ 5,473,200
Proceeds from stockholder loans
Net cash provided by financing activities	$ 5,473,200
Effect of exchange rate changes on cash	(184,624)	$ (17,980)
Net change in cash	5,511,557	(48,004)
Cash, Beginning of Period	8,669,034	3,012,812
Cash, End of Period	$ 14,180,591	$ 2,964,808
Supplemental Disclosures of Cash Flow Information:
Cash paid for interest
Cash paid income taxes	$ 113,712	$ 87,941
Noncash financing activities:
Payment of accrued expenses and other payables by shareholder	$ 20,000	$ 25,417